

Claims

1. A pharmaceutical composition for enhancement of glucose uptake into warm-blooded animal cells comprising as an active ingredient one or more HMG-CoA reductase inhibitor(s).
2. A pharmaceutical composition for enhancement of glucose uptake into warm-blooded animals cells in the presence of insulin comprising as an active ingredient one or more HMG-CoA reductase inhibitor(s).
3. A pharmaceutical composition according to claim 1 or 2, wherein the HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, pitavastatin and rosuvastatin.
4. A pharmaceutical composition according to claim 1 or 2, wherein the HMG-CoA reductase inhibitor is a water-soluble HMG-CoA reductase inhibitor.
5. A pharmaceutical composition according to claim 1 or 2, wherein the HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin.
6. A pharmaceutical composition according to claim 1 or 2, wherein the HMG-CoA reductase inhibitor is pravastatin.
7. A pharmaceutical composition for the treatment of diabetes, hyperglycemia, glucose intolerance or gestational diabetes mellitus, or the treatment or prevention of diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease), comprising as an active ingredient one or more medicament(s) selected from the group consisting of pravastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, pitavastatin and rosuvastatin.

8. A pharmaceutical composition for the treatment of diabetes, hyperglycemia, glucose intolerance or gestational diabetes mellitus caused by insulin resistance syndrome, or the treatment or prevention of diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease) caused by insulin resistance syndrome, comprising as an active ingredient one or more medicament(s) selected from the group consisting of pravastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, pitavastatin and rosuvastatin.

9. A pharmaceutical composition for the treatment of diabetes, hyperglycemia, glucose intolerance or gestational diabetes mellitus, or the treatment or prevention of diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease), comprising as an active ingredient one or more water-soluble HMG-CoA reductase inhibitor(s).

10. A pharmaceutical composition for the treatment of diabetes, hyperglycemia, glucose intolerance or gestational diabetes mellitus caused by insulin resistance syndrome, or the treatment or prevention of diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease) caused by insulin resistance syndrome, comprising as an active ingredient one or more water-soluble HMG-CoA reductase inhibitor(s).

11. A pharmaceutical composition according to claim 9 or 10, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin.

12. A pharmaceutical composition according to claim 9 or 10, wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin.

13. A method for enhancing glucose uptake into warm-blooded animal cells comprising administration of an effective amount of one or more HMG-CoA reductase inhibitor(s) to a warm-blooded animal.
14. A method for enhancing glucose uptake into warm-blooded animal cells in the presence of insulin comprising administration of an effective amount of one or more HMG-CoA reductase inhibitor(s) to a warm-blooded animal.
15. A method according to claim 13 or 14, wherein the HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, pitavastatin and rosuvastatin.
16. A method according to claim 13 or 14, wherein the HMG-CoA reductase inhibitor is a water-soluble HMG-CoA reductase inhibitor.
17. A method according to claim 13 or 14, wherein the HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin.
18. A method according to claim 13 or 14, wherein the HMG-CoA reductase inhibitor is pravastatin.
19. A method for the treatment of diabetes, hyperglycemia, glucose intolerance or gestational diabetes mellitus, or the treatment or prevention of diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease), comprising administration of an effective amount of one or more medicament(s) selected from the group consisting of pravastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, pitavastatin and rosuvastatin to a warm-blooded animal.
20. A method for the treatment of diabetes, hyperglycemia, glucose intolerance or gestational diabetes mellitus caused by insulin resistance syndrome, or the treatment or

prevention of diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease) caused by insulin resistance syndrome, comprising administration of an effective amount of one or more medicament(s) selected from the group consisting of pravastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, pitavastatin and rosuvastatin to a warm-blooded animal.

21. A method for the treatment of diabetes, hyperglycemia, glucose intolerance or gestational diabetes mellitus, or the treatment or prevention of diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease), comprising administration of an effective amount of one or more water-soluble HMG-CoA reductase inhibitor(s) to a warm-blooded animal.

22. A method for the treatment of diabetes, hyperglycemia, glucose intolerance or gestational diabetes mellitus caused by insulin resistance syndrome, or the treatment or prevention of diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease) caused by insulin resistance syndrome, comprising administration of an effective amount of one or more water-soluble HMG-CoA reductase inhibitor(s) to a warm-blooded animal.

23. A method according to claim 21 or 22, wherein the water-soluble HMG-CoA reductase inhibitor is a medicament selected from the group consisting of pravastatin and rosuvastatin.

24. A method according to claim 21 or 22, wherein the water-soluble HMG-CoA reductase inhibitor is pravastatin.

25. A method according to any one of claims 13 to 24, wherein the warm-blooded animal is a human.